News & Press
Abbisko Therapeutics Announces Initiation of Phase 1 Trial for ABSK021, its Selective CSF-1R Small Molecule Inhibitor
August 16, 2019, Shanghai, China. – Abbisko Therapeutics, a clinical-stage biopharmaceutical company focused on creating innovative medicine for unmet medical needs in China and around the world, today announced that it has received regulatory approval from US FDA to initiate its Phase 1 trial for ABSK021, a CSF-1R small molecule inhibitor for treating multiple types of tumors, and expects to start dosing patients shortly.
ABSK021 is independently discovered and developed by Abbisko Therapeutics with full intellectual property rights worldwide. It is an orally administrated, highly potent, and selective small molecule inhibitor of CSF-1R with best-in-class drug-like properties. Through CSF-1R inhibition, ABSK021 could reprogram tumor-associate macrophages (TAMs) and other immune cells, modulate tumor microenvironment, and relieve tumor immunosuppression.
Based on its mechanism of action and a large number of preclinical findings, Abbisko is advancing ABSK021 into a Phase 1 clinical study in patients with advanced malignancies and Tenosynovial Giant Cell Tumors (TGCT) where TAMs are known to be likely contributors of tumorigenesis.